Search results
Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 89% of the company
Simply Wall St. via Yahoo Finance· 9 months agoKey Insights Significantly high institutional ownership implies Biogen's stock price is sensitive to...
Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Given the large stake in the stock by institutions, Biogen's stock price might be...
Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 5 months agoIn the latest trading session, Biogen Inc. (BIIB) closed at $260.58, marking a -0.52% move from the...
Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks via Yahoo Finance· 5 months agoBiogen Inc. (BIIB) ended the recent trading session at $255.84, demonstrating a -0.83% swing from...
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks via Yahoo Finance· 4 months agoBiogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings...
Better Alzheimer's Disease Stock: Eli Lilly or Biogen?
Motley Fool· 2 years agoSeveral big-name companies are racing to develop effective therapies for Alzheimer's disease (AD), a...
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
Investor's Business Daily· 12 months agoBiogen stock bounded higher Wednesday after the Food and Drug Administration posted "relatively...
3 Reasons to Buy Biogen Stock (and 1 to Sell)
Motley Fool· 1 year agoBiogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Aduhelm's accelerated approval sent the stock soaring a few years ago,...
Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 10 months agoBiogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple...
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
Zacks via Yahoo Finance· 4 months agoBiogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its...
